Kailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range. Strong investor demand reflects growing excitement around weight-loss and GLP-1 drugs, a market expected to expand rapidly as firms challenge pharma giants like Eli Lilly and Novo Nordisk.